Theravance Biopharma, Inc.

Theravance Biopharma, Inc.

TBPHNYSE / NASDAQHealthcareSmall cap

$17.03$0.00 (0.0%)

Last close · Data as of Sep 25, 2026

Market cap
$843.9M
P/E
8.0x
EV / EBITDA
5.3x
Revenue
$107.5M
Net margin
98.5%
ROCE
-0.8%

Hidden because the last close is more than three trading days older than the latest prices of its class.

Theravance Biopharma, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 25 Sep 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change $0.00 (0.0%) from $17.03 to $17.03 · Last close Sep 25, 2026

Best weekday to invest, historically

The same weekly amount in TBPH, bought on each weekday since 2021.

News & filings

What Theravance Biopharma filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was 53.5 times interest costs.

Concerns (1)

  • Net profit fell 50.5% a year over three years.
  • Prices are as of 25 Sep 2026; price-based points are paused until newer prices arrive.

Prices to the 25 Sep 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.

Read moreShow less

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Sector
Healthcare
Shares outstanding
50.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$843.9M
P/E
8.0x
P/B
2.8x
EV / EBITDA
5.3x
EV / Sales
6.7x
P/S
7.9x
52-week high
$20.74
52-week low
$13.57

Profitability

Operating margin
-3.4%
Net margin
98.5%
EBITDA margin
125.2%
ROE
35.7%
ROCE
-0.8%
ROIC
62.9%
ROA
21.8%
Asset turnover
0.22

Growth

Revenue
$107.5M
Revenue growth, 1Y
66.9%
Revenue CAGR, 3Y
27.9%
Net profit growth, 1Y
-287.7%
Free cash flow
$238.5M

Solvency

Current ratio
10.93
Debt / Equity
0.14
Debt / Assets
0.09
CFO / Net profit
2.25
Cash / Market cap
19.9%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$107.5M
Gross profit$107.5M
Operating expenses$111.1M
Research and development$37.4M
Selling, general and administrative$73.7M
Operating income-$3.6M
Interest and other$132.8M
Pretax income$129.3M
Tax and other$23.3M
Net income$105.9M

Revenue and net profit

Revenue grew 66.9% in FY2025; net profit is the dashed line.

Theravance Biopharma, Inc. revenue and net profit by fiscal year
Theravance Biopharma, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$51.3M$872.1M
FY2023$57.4M-$55.2M
FY2024$64.4M-$56.4M
FY2025$107.5M$105.9M

Cash flows

FY2025: $238.5M from operations, $238.5M free after investment (dashed).

Theravance Biopharma, Inc. operating and free cash flow by fiscal year
Theravance Biopharma, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$187.0M-$187.6M
FY2023-$27.0M-$29.5M
FY2024-$11.5M-$11.9M
FY2025$238.5M$238.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$107.5M+66.9%1Y
EBITDA
$134.5M
Net profit
$105.9M
Cash from operations
$238.5M
Free cash flow
$238.5M
Revenue CAGR, 3Y
27.9%
Net profit CAGR, 3Y
-50.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$107.5M$134.5M$105.9M$238.5M35.7%+66.9%-287.7%

Monthly returns

Month-by-month returns of TBPH across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$485.6M
Liabilities$188.8M
Equity$296.7M
Paid-in capital$1.2B
Retained earnings-$859.6M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; TBPH highlighted.

P/E against peers

TBPH trades at 8.0x earnings against a peer median of -6.9x.

  1. Theravance Biopharma, Inc. (this company)8.0x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): ORIC Pharmaceuticals, Inc., LB Pharmaceuticals Inc, Sana Biotechnology, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Theravance Biopharma, Inc.TBPHthis company$843.9M8.0x2.8x35.7%5.3x
Certara, Inc.CERT$872.7M-547.2x0.8x-0.2%9.7x
Talkspace, Inc.TALK$871.1M111.8x7.4x6.7%129.1x
Arbutus Biopharma CorporationABUS$859.3M-25.6x11.2x-43.7%-25.5x
Janux Therapeutics, Inc.JANX$839.1M-7.4x0.9x-11.9%-5.2x
ORIC Pharmaceuticals, Inc.ORIC$830.2M-6.4x2.2x-33.7%-5.6x
LB Pharmaceuticals IncLBRX$828.8M-32.9x2.8x-8.4%-19.4x
Amphastar Pharmaceuticals, Inc.AMPH$824.5M8.4x1.0x12.4%6.2x
Sana Biotechnology, Inc.SANA$823.7M-3.4x5.1x-151.8%-4.3x
Peer median—-6.9x2.5x-10.1%-4.8x

Year-to-date ROI

TBPH since 1 January, against earlier years.

Historical volatility

TBPH's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Theravance Biopharma, Inc. operating margin by fiscal year
Theravance Biopharma, Inc. operating margin by fiscal year
DateOperating margin
FY2022-154.1%
FY2023-92.8%
FY2024-65.9%
FY2025-3.4%
LineFY2025
Operating expensesOperating Expense$111.1M
Research and developmentResearch And Development$37.4M
Selling, general and administrativeSelling General And Administration$73.7M
Total expensesTotal Expenses$111.1M
Pretax incomePretax Income$129.3M

Learn while you research

Academy chapters picked for Theravance Biopharma, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 8.0 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Growth Investing67% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →